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The presence of minimal residual disease (MRD) before transplantation is the most important prognostic risk
factor predictive of post-transplantation relapse in hematologic malignancies. However, MRD alone does not
adequately predict relapse in all patients. To improve upon the ability to identify patients likely to relapse, we
evaluated risk factors, in addition to MRD, that may be associated with development of post-transplantation
relapse. In this single institution, retrospective cohort study of children with acute leukemia or myelodys-
plastic syndrome who had undergone a ﬁrst allogeneic transplantation and had pretransplantation MRD
evaluation, 40 of 93 patients (43%) experienced relapse. Univariate analysis demonstrated that African
American race, high initial white blood cell count, central nervous system (CNS) disease at diagnosis, short
ﬁrst complete remission, nonmyeloablative (NMA) conditioning, lack of remission, and MRD before trans-
plantation were associated with worse relapse-free survival (RFS). In a Cox multivariable analysis, CNS disease
(P ¼ .009), lack of remission (P ¼ .01), and NMA conditioning (P ¼ .04) were independently associated with
inferior RFS. Among those in a morphologic complete remission who underwent a myeloablative trans-
plantation, having both CNS disease at diagnosis (speciﬁcally in acute lymphoblastic leukemia) and MRD
positivity was an independent risk factor predictive of relapse, which has not been previously reported.
Results from our study support the existence of risk factors complimentary to pretransplantation MRD.
Validation in a larger independent homogenous cohort is needed to develop a prognostic tool for clinical use
to predict post-transplantation relapse.
Published by Elsevier Inc. on behalf of American Society for Blood and Marrow Transplantation.INTRODUCTION
Despite the curative intent with which allogeneic he-
matopoietic cell transplantation (HCT) is performed for the
treatment of hematologic malignancies, relapse is the pri-
marycause of treatment failure [1,2]. Relapse rates range from
10% to 60%, depending on the type and stage of disease at the
timeof transplantation, and this has remained steadyover the
decades despite overall improvement in transplantation
outcomes. Treatment options for post-transplantation
relapse are limited and outcomes are poor [3-6]. Early inter-
vention strategies for relapse prevention in those at highest
risk of relapse may be indicated to improve relapse-free sur-
vival (RFS) [7-9].
The ability to stratify patients by degree of risk of post-
transplantation relapse may inform post-transplantationdgments on page 1038.
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risk. Many risk factors, such as disease subtype, disease sta-
tus [10,11], conditioning regimens [12-14], cytogenetics [15],
duration of remission, and timing of transplantation [16,17]
have been found to be independently associated with
relapse, but a prognostic score incorporating these risk fac-
tors to stratify patients is lacking. Emerging data on the
presence of pretransplantation minimal residual disease
(MRD) as predictive of relapse is most compelling [18,19].
However, even MRD alone is not completely predictive of
post-transplantation relapse. Recent data have shown that in
the current era, survival rates have improved for MRD-
positive patients, suggesting that MRD positivity should not
be a contraindication for transplantation [18,20]. Clearly,
reﬁnement upon MRD is needed to further stratify risk.
In this retrospective analysis of pediatric patients with
acute leukemias and myelodysplastic syndrome who un-
derwent an allogeneic HCT, we sought to identify risk factors
predictive of post-transplantation relapse, inclusive of pre-
transplantation MRD. The goals were to be able to deﬁne the
subset of patients at highest risk of relapse who may beneﬁt
from novel approaches for relapse prevention.Society for Blood and Marrow Transplantation.
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Patients and Inclusion Criteria
This was a retrospective cohort analysis of pediatric patients (ages less
than or equal to 21 years at the time of transplantation) with hematologic
malignancies who underwent a ﬁrst allogeneic HCT between the years of
2003 and 2010 at Johns Hopkins Hospital (JHH) and who had at least 1 post-
transplantation disease evaluation. Diagnosis included acute lymphoblastic
leukemia (ALL), acute myelogenous leukemia (AML), myelodysplastic syn-
drome (MDS), mixed phenotypic acute leukemia (MPAL), lymphoblastic
lymphoma, or Burkitt’s lymphoma. Patients with other types of leukemia,
including blast crisis chronic myelogenous leukemia, were excluded. Pa-
tients with lymphoma were analyzed together with patients with ALL. This
study was approved by the JHH Institutional Review Board.
Pretransplantation Disease Status
Pretransplantation disease status was assessed in all patients. In patients
with ALL, MRD was assessed in our central reference lab using ﬂow cyto-
metric measures using methods that have been previously described [21].
Following deﬁnitions published by Leung et al. [18], the MRD level was
considered positive if the level was  .01%. For AML, the sensitivity of
detection for ﬂow cytometry ranged from approximately .1% to 1% of cells,
depending upon the phenotype of the initial leukemia.
Other methods of disease detection included cytogenetic, molecular,
and radiographic methods, including ﬂuorescence in-situ hybridization
(FISH) and reverse transcriptase polymerase chain reaction (RT-PCR).
Accordingly, 5 patients whowere in a morphologic complete remissionwith
no evidence of ﬂow cytometric MRD were found to have evidence of disease
by 1 of these alternative measures before transplantation. Disease status for
patients with MDS was not included in any analysis, as the standard of care
for these patients was to go directly to transplantation without any prior
therapy.
Central nervous system (CNS) disease was deﬁned using Children’s
Oncology Group deﬁnitions. For ALL, only CNS 3 (deﬁned as having a total
cerebrospinal ﬂuid white cell count  5/mL and blasts on cytospin) was
considered positive. For AML, any number of blasts on a cytospin in an
atraumatic lumbar puncture was considered positive. CNS positivity was
also determined any clinical signs of CNS leukemia (eg, ocular involvement)
or radiographic evidence of an intracranial mass consistent with a chloroma.
Transplantation and Post-transplantation Characteristics
Transplantation characteristics, including pretransplantation perfor-
mance status, conditioning regimen, cytomegalovirus status, donor age and
gender, stemcell source, andHLA typingwere collected.High-resolutionHLA
typingwas available for all donors and recipients from 2005 and later. Before
that, typing was either by serological methods or low-resolution molecular
typing. Information on the presence or absence of graft-versus-host disease
(GVHD) and grading was also collected on each patient.
Relapse Deﬁnition
Relapse was deﬁned by the presence of any evidence of disease after
transplantation. This was inclusive of post-transplantationMRD, as detected
by ﬂow cytometric, molecular, or cytogenetic measures. Though detection of
post-transplantation MRD is not consistent with the conventional
morphologic deﬁnition of relapse (ranging from > 5% to > 25% disease by
morphology), the decision to include patients with post-transplantation
MRD in our deﬁnition of relapse was done because it is consistent with
the primary objectives of being able to identify those patients at highest risk
of relapse. Detection of MRD after transplantation is highly associated with
overt relapse [22] and identiﬁes a very high-risk population in whom
disease-speciﬁc interventions are frequently utilized to reduce the risk for
progression of MRD to overt relapse. This decisionwas further justiﬁed as all
patients with acute leukemia and post-transplantation MRD rapidly pro-
gressed to overt relapse (median time, 21 days to overt relapse from ﬁrst
detection at MRD).
Routine post-transplantation surveillance, at approximately day þ30,
day þ60, day þ90, day þ180, and at þ1 and þ2 years after transplantation,
and then as clinically indicated, was disease speciﬁc and included evaluation
of bone marrow chimerism and ﬂow cytometric, cytogenetic, and molecular
MRD studies (eg, bcr/abl in Philadelphia chromosomeepositive ALL). In
addition, lumbar punctures were routinely performed on these days to
assess for CNS disease in all patients. The time to relapse was determined
from the date of transplantation until the date of relapse, as documented by
the ﬁrst date of disease recurrence.
Statistical Analysis
The primary endpoint was post-transplantation relapse. A cumulative
incidence curve of relapse, adjusted for the competing risk of death due to
treatment-related mortality (TRM), was constructed using the method ofGooley [23]. In addition, the probability of RFS as a function of time was
determined by the Kaplan-Meier method. The association between pre-
treatment characteristics and RFSwas determined using the log-rank test. In
the Kaplan-Meier analyses, those patients who died of TRM were censored
at the time of death with disease information captured from themost recent
evaluation before death. Those without relapse were censored at their date
of last follow-up.
When patients were divided into 2 groups after examining their initial
association with RFS in more than 2 groups, the subsequent P values were
adjusted to account for these multiple comparisons by multiplying the
resulting unadjusted P value by the number of tests implicitly performed to
arrive at the ﬁnal grouping. The Cox proportional hazardsmodel was used to
determine the joint signiﬁcance of factors associated with development of
relapse. Those individual factors that had P < .10 in the univariate analyses
were considered for inclusion in the joint model.
All P values are 2-tailed, and except as noted above, presented without
adjustment for multiple comparisons.
RESULTS
Patient and Disease Characteristics
Ninety-three children were included (Table 1). Diagnoses
included ALL (n ¼ 34), including lymphoblastic lymphoma
(n ¼ 2), Burkitt’s lymphoma (n ¼ 1), AML (n ¼ 41), MPAL
(n ¼ 10), and MDS (n ¼ 8). Notably, 8 of the patients with
AML had a prior diagnosis of MDS that transformed to AML
before transplantation. Seventeen patients had a history of
treatment-related or secondary MDS/AML. Indications for
transplantation, with some patients having more than 1
indication, included primary induction failure (n ¼ 25), of
which 8 never attained a remission; high-risk disease, in-
clusive of patients with high-risk cytogenetics (eg, mono-
somy 7) and those with induction failure (n ¼ 49); relapsed
disease, inclusive of patients who underwent transplantation
in ﬁrst relapse and beyond (n ¼ 38); and refractory relapsed
disease or secondary induction failure (n ¼ 9). Twenty-four
patients had CNS disease at diagnosis (6 with ALL, 15 with
AML, and 3 with MPAL). No patients had detectable CNS
disease at the time of transplantation.
Transplantation and Post-transplantation
Characteristics
The median age at transplantation was 10 years (range,
7 months to 21 years). Seventy-nine patients (85%) under-
went a myeloablative preparative regimen (MA), and 14
(15%) underwent nonmyeloablative preparative regimen
(NMA). Forty-ﬁve patients (48%) received total body irradi-
ation as part of the preparative regimen (30 with ALL). Those
who received an NMA regimen included 6 patients with a
performance status 70%, 3 patients who underwent
transplantation for MDS (based on the decision of the
treating physician that MA conditioning was not indicated),
and 5 who underwent transplantation on an experimental
NMA haploidentical protocol that was open at our institution
for patients who needed an alternative donor source (MA
protocol was not available at the time). This included 1
subject with MPAL, 2 subjects with ALL, and 8 subjects with
AML. Based on those who survived to day 45, 32 of 83 pa-
tients developed acute GVHD, of which the vast majority
(75%) had maximum grade 2 GVHD [24].
Relapse Characteristics
Fortyof 93 (43.0%) patients relapsed afterHCT. Themedian
time to relapse was 144 days (4.6 months) after HCT and
ranged from 1 day after HCT (including 1 patient who had
progressive disease during transplantation conditioning) to
57 months after HCT. The cumulative incidence of relapse,
adjusting for TRM, was 17%, 26%, and 36% at 3, 6, and
12 months after transplantation, respectively. (Figure 1).
Table 1
Baseline Characteristics and Factors Associated with Relapse-Free Survival
Characteristic All (n) Patients without Relapse
during Follow-up (n)
Patients with Relapse
during Follow-up (n)
Log-rank P Value for Comparison
of Relapse-Free Survival
Total (n) 93 53 40 —
Male gender (n) 62 33 29 NS
Race
Non-African American 76 47 29 .03
African American* 17 6 11
Disease
Acute lymphoblastic leukemia 34 18 16 NS
Acute myelogenous leukemia 41 23 18
Mixed phenotypic acute leukemia 10 6 4
Myelodysplastic syndrome 8 6 2
At diagnosis
WBC count
>65,000* 18 7 11 .04
<65,000 54 34 20
CNS disease
Yes* 24 10 14 .03
No 61 39 22
Duration of ﬁrst complete remissiony
>450 d 19 12 7 .06
<450 d* 19 6 13
No. of induction regimens given to induce remission
0 (MDS only) 7 6 1 .02
1 27 19 8
2 36 18 18
3þ 23 10 13
At HCT
Morphologic remission
Yes 74 44 30 .0006
No* 11 3 8
Minimal residual disease
>.01%* 34 14 20 .015
<.01% 50 32 18
Performance status
80%-100% 84 51 33 .02
40%-70%* 8 2 6
HCT typez
Myeloablative 79 49 30 .0004
Nonmyeloablative* 14 4 10
Stem cell source
Bone marrow 71 37 34 NS
Single umbilical cord 18 12 6
Double umbilical cord 1 1 0
Peripheral blood 3 3 0
Donor type
Matched sibling 26 15 11 NS
Matched unrelated 30 18 12
Cord blood 19 13 6
Haploidentical 15 6 9
Mismatched related/unrelated 3 1 2
NS indicates not signiﬁcant; WBC, white blood cell; CNS, central nervous system; MDS, myelodysplastic syndrome; HCT, hematopoietic cell transplantation.
* Denotes the category associated with higher relapse risk and worse relapse-free survival.
y Limited to those attaining a ﬁrst complete remission with subsequent pre-HCT relapse
z Nonmyeloablative transplantations were performed in 1 subject with mixed phenotypic acute leukemia, 2 subjects with acute lymphoblastic leukemia, 3
subjects with myelodysplastic syndrome, and 8 subjects with acute myelogenous leukemia.
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Forty-three of 93 (46.2%) patients are alive with a median
follow-up time of 42 months (range, 13 to 114 months) after
transplantation. Notably, this includes 5 of 40 (12.5%) patients
with post-transplantation relapse. Ten patients died from
TRM within the ﬁrst 100 days. Cumulative incidence of mor-
tality not attributed to post-transplantation disease progres-
sion was 8.6%, 11.8%, and 12.9% at 3, 6, and 12 months,
respectively. (Figure 1) For these patients, the etiology of late
death beyond 1 year after transplantation included recurrent
CNStumor (n¼1), infection (n¼1), andchronicGVHD(n¼2).
Univariate Analysis of Factors Related to Relapse
Factors evaluated for association with RFS included race,
gender, disease type, cytogenetics, remission status and MRD,duration of remission, initial WBC count and CNS status at
diagnosis, initial response to therapy (induction failure or
relapsed disease), remission number at the time of trans-
plantation, performance status, conditioning regimen (MA
versus NMA), use of total body irradiation, stem cell source,
donor source, gender match, HLA match, and GVHD (Table 1).
Univariate actuarial analysis demonstrated that the
following factors were statistically signiﬁcantly associated
with higher relapse probability: CNS disease at diagnosis
(Figure 2), high WBC, African American race (Figure 3), short
ﬁrst complete remission duration of < 450 days (limited to
those who attained ﬁrst complete remission with subse-
quent pre-HCT relapse), greater number of regimens given to
induce remission (Figure 4), poorer performance status, NMA
preparative regimen, lack of remission, and presence of MRD
Figure 1. Cumulative incidence of relapse and transplantation-related mortality (TRM). Cumulative incidence of relapse and TRM were analyzed at competing risks
starting at the date of transplantation for 93 consecutive patients who underwent a ﬁrst allogeneic HCT for acute leukemia or MDS. Cumulative incidence of relapse
was 17%, 26%, and 37% by 3, 6, and 12 months after transplantation respectively.
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in relapse among all patients when evaluated by disease
subtype (global P ¼ .77; Supplemental Figure 1). A landmark
analysis was performed to evaluate the role of acute GVHD
on relapse, restricted to patients who survived to at least day
45 (n¼ 84). Based on this analysis, the presence of aGVHD by
day 45 was not found to statistically affect the probability of
relapse.Cox Multivariable Analysis of Factors Associated with
Relapse: All Patients
Based upon the univariate Kaplan-Meier and log-rank test
results, those parameters found to be statistically associated
with higher relapse rate (P < .10) were considered for in-
clusion in the Cox model (Table 1). By backward selection, a
model that described the joint effect of the parameters on
increased relapse risk identiﬁed the presence of CNS disease
at diagnosis (P ¼ .009), lack of morphologic remission (P ¼
.01), and NMA HCT (P ¼ .04) as remaining in the ﬁnal model
(Table 2).Figure 2. Kaplan-Meier relapse-free survival curve for patients who had CNS
disease at diagnosis (n ¼ 24) compared with those who did not (n ¼ 61).Subset Analysis: Including Only patients Who Underwent
a Myeloablative Transplantation and Were in a
Morphologic Complete Remission at the Time of
Transplantation
To reduce the confounding effect of active disease and
NMA conditioning on relapse risk, a post hoc subset analysis
was performed including only those in a morphologic
remission who underwent an MA transplantation. In this
group, 24 of 70 (34%) children experienced relapse. Cox
models identiﬁed that either 2 or more regimens needed to
achieve remission or the presence of both pre-HCT MRD
and CNS disease were approximately equally predictive of
increased relapse risk. For the model based on pre-
transplantation MRD and CNS disease, P ¼ .02, the hazard
ratio was 3.05 and the 95% conﬁdence interval for the hazard
ratio was 1.19 to 7.86 (Figure 5). Speciﬁcally, within this
subset, the presence of detectable MRD was associated with
approximately 2-fold higher disease-speciﬁc relapse risk
(Table 3). In the disease-speciﬁc analysis, for patients with
ALL (n ¼ 31), CNS disease was more highly associated with
relapse risk than MRD, and it was the only factor thatFigure 3. Kaplan-Meier relapse-free survival curve for patients who are Af-
rican American (n ¼ 17) compared with those who are not (n ¼ 76).
Figure 4. Kaplan-Meier relapse-free survival (RFS) curve, stratiﬁed by the
number of induction regimens given to induce remission. Patients with MDS
had no prior regimens (n ¼ 7) before going to transplantation. Twenty-seven
patients went directly to transplantation after 1 induction attempt, which
included primarily patients with AML with high-risk cytogenetics and
matched sibling donors who were sent directly to transplantation in remis-
sion. Thirty-six patients had 2 induction regimens (which was inclusive of
those who were reinduced at the time of relapse), and 23 patients had 3 or
more induction attempts (and included patients with primary induction fail-
ure and those with refractory or active disease at the time of transplantation).
Table 2
Cox Model
Parameter P Value Hazard
Ratio (HR)
95% Conﬁdence
Limits for HR
CNS disease .0089 2.77 1.28-5.59
Morphologic remission (lack of) .013 .27 .10-.77
Myeloablative conditioning
(having an NMA conditioning)
.041 2.62 1.04-6.58
CNS indicates central nervous system; NMA, non-myeloablative.
Multivariable analysis including parameters associated with post-
transplantation relapse in univariate analyses, based on all patients with
complete data.
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other factors. The hazard ratio for CNS disease in patients
with ALL was 9.48 (95% conﬁdence interval, 2.81 to 32.02).
Notably, these patients relapsed in the marrow and not the
CNS. For those who were MRD negative, based on 19 total
patients, the presence of CNS disease at diagnosis (n¼ 2) was
signiﬁcantly associated with higher relapse risk (P < .0001).
No suchmodel could be developed for AML (7 of 26 relapsed)
because of the limited numbers.
DISCUSSION
Risk stratiﬁcation forms the foundation of pediatric
oncology. The ability to modify therapy based on identifying
patients at high-risk of treatment failure has reduced the risk
of relapse, leading to overall improved outcomes. Given the
poor outcomes of post-transplantation relapse, a similar
approach is needed to identify those at high-risk of relapse,
inwhom relapse prevention strategies may be indicated. Our
analysis provides 1 of the ﬁrst comprehensive multivariable
analyses including pretransplantation MRD to identify po-
tential factors in the transplantation setting that may be used
to identify those with leukemia at highest risk of post-
transplantation relapse. Among our ﬁndings, the association
of CNS disease at diagnosis with higher post-transplantation
relapse risk has not previously been reported, and other asso-
ciations, such as African American race, warrant further study.
Regarding the association of CNS disease at diagnosis and
its association with post-transplantation relapse, its role was
particularly notable in patients with ALL, where the presence
of CNS disease at diagnosis was more predictive of relapse
than pretransplantation MRD. This ﬁnding, in a small num-
ber of patients, would require independent conﬁrmation.
Notably, these patients all had marrow relapse.
One possible explanation for this association is that CNS
involvement at diagnosis reﬂects biologic higher-risk dis-
ease. Alternatively, as a sanctuary site, the CNS may be less
amenable to a graft-versus-leukemia effect. Furthermore,
current cytologic methods of CNS disease monitoring may
not be sensitive enough to detect MRD in the CNS before
transplantation, and the cerebrospinal ﬂuid could potentially
serve as a reservoir for persistent subclinical disease. Treat-
ment of CNS, either via CNS-directed therapy given as a seriesof 5 weekly post-transplantation lumbar punctures with
the administration of intrathecal therapy (standard practice
at JHH), or other post-transplantation regimen or via pre-
transplantation CNS therapy, has limited and unproved efﬁ-
cacy, and it may not help to prevent early relapse [25-27].
When ﬂow cytometric methods of disease detection in the
CNS are used to improve the sensitivity of disease detections,
it both improves upon accuracy of disease detection and can
serve as a prognostic tool in outcomes in hematologic ma-
lignancies [28-30]. To further evaluate this, a biology study to
look for evidence of pretransplantation MRD in the CNS by
ﬂow cytometry is being planned at our institution.
Additionally, this is, to our knowledge, the ﬁrst study to
report an association between African American race and
higher risk of post-transplantation relapse. In our cohort, 11
of 17 (65%) African Americans experienced relapse, which
was signiﬁcantly higher than the relapse rate for noneAfrican
Americans. Although this association did not carry indepen-
dent signiﬁcance in the multivariable analysis, this study was
small and was not designed to fully investigate this associa-
tion. Despite this, the ﬁndings are noteworthy, given the
known racial disparities that exist for the African American
population in the transplantation setting. This includes
higher TRM, a lower likelihood of ﬁnding a matched unre-
lated donor, and less access to allogeneic transplantation [31].
In this regard, because of the lack of readily availablematched
donors for those needing transplantation, African Americans
were disproportionately enrolled on our early phase trials of
NMA haploidentical transplantation protocols. Additionally,
prior data suggest poorer outcomes for African Americans
undergoing conventional chemotherapy for hematologic
malignancies [32,33]. In these settings, differences in out-
comes between races have been largely ameliorated with
treatment intensiﬁcation and equal access to comprehensive
care, suggesting that inherent biologic factors that lead to
higher risk disease can be overcome by treatment intensiﬁ-
cation [34]. Alternatively, differences in drug metabolism
preventing the optimal drug exposure needed to eradicate
disease may also explain this difference. Pharmacogenomic
variability leading to differences in cyclophosphamide
metabolism has been seen [35], which hasmajor implications
for use of cyclophosphamide in conditioning regimens.
Ultimately, given the importance of pretransplantation
disease status for post-transplantation relapse, the inherent
strengthof ourpaper is that pretransplantationMRDdatawas
performedand available on all patients. Focusingprimarily on
those patients with leukemia who were in a morphologic
complete remission and had undergone an MA trans-
plantation, the presence of pretransplantation MRD nearly
doubled the crude relapse risk,with thehighest risk of relapse
seen in patients with ALL who were MRD positive (64%),
consistent with previously published data [18,20,36,37].
Figure 5. Kaplan-Meier relapse-free survival curve for patients with leukemia who underwent a myeloablative conditioning regimen and were in a morphologic
remission at the time of transplantation, comparing outcomes of those who were both MRD positive and CNS positive (at diagnosis) (25% relapse-free at 24 months)
to those who were not both CNS positive and MRD positive (67% relapse-free at 24 months).
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solely onMRDwas not adequate. In our study, consistentwith
other results,13 patientswith acute leukemiawhowereMRD
negative still experienced post-transplantation relapse, rep-
resenting 33% of all those who relapsed.
Looking closely at factors associated with MRD, we found
that a greater number of induction regimens required to
induce remission was associated with increased relapse risk,
as well as with MRD status. In this regard, our analysis pro-
vides some evidence that the strategy of providing additional
chemotherapy to eliminate pretransplantation MRD has not
been proven to improve post-transplantation relapse. The
need for multiple induction attempts to attain an MRD-
negative status may serve as an indication of high-risk dis-
ease. A patient who attains an MRD-negative remission after
1 induction attempt, is, therefore, very different from a pa-
tient who requires multiple induction attempts to get to an
MRD-negative status. Despite both types of patients attain-
ing MRD negativity, they may not have biologically equal-
risk disease. On a related note, there was a 45% probability
of remaining relapse free at 18 months and beyond among
patients who were MRD positive, suggesting that the mere
presence of detectable MRD does not mean that trans-
plantation is futile. Our analysis provides further evidenceTable 3
Crude Relapse Rates for Patients Who Have Undergone a Myeloablative
AlloHCT and Are in a Morphologic Complete Remission Pre-alloHCT, by
Minimal Residual Disease Status
Disease MRD Status Total
(n)
Relapse
(n)
Crude
Relapse
Rate
ALL Negative 20 7 35%
Positive 11 7 64%
AML Negative 15 3 20%
Positive 11 4 36%
MRD indicates minimal residual disease; ALL, acute lymphoblastic leuke-
mia; AML, acute myelogenous leukemia; MPAL, mixed phenotypic acute
leukemia; AlloHCT, allogeneic hematopoietic cell transplantation.
MRD considered positive when  .01% in ALL and  .1% in AML/MPAL.for the need of reﬁnement of MRD as a prognostic tool. This
is especially important in being able to distinguish which
MRD-positive patient would beneﬁt from going directly to
transplantation with a potential for cure, versus directing
them towards additional disease-directed therapy in an
attempt to eradicate MRD to reduce risk of post-
transplantation relapse, albeit at the risk of accumulation
of toxicity and, potentially, disease progression.
Limitations to our study include the retrospective design
incorporating a heterogeneous patient population, and
including both patients with refractory disease and/or those
who have undergone an NMA/reduced-intensity condition-
ing. A subset analysis of those in a complete remission un-
dergoing an MA transplantation was performed to eliminate
these confounders. Additionally, development of disease-
speciﬁc risk scores was limited because of the small sample
size; but, we were able to demonstrate a clear association
between CNS disease at diagnosis and relapse in the subset of
patients with ALL who underwent an MA transplantation.
Clearly, this analysis needs to be performed in a larger cohort
to validate our ﬁndings. Lastly, post-transplantation factors,
such as the presence or absence of GVHD (with potentially
concurrent graft-versus-leukemia effect) can also affect
relapse [38-41]. Although this was not found to affect relapse
in this study, the heterogeneity of the patient population and
small sample sizemay have not been able to demonstrate the
effect of this known risk factor.
In conclusion, this analysis has led to discovery of addi-
tional risk factors other than MRD that may help to further
reﬁne the risk of relapse to help identify subgroups that are
at higher risk of relapse. Further study and validation of risk
factors in disease-speciﬁc cohorts with a larger population is
warranted, with the ultimate goal being to develop and
validate a prognostic score for use in the development of
relapse prevention trials.
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